BACKGROUND: Although the therapeutic outcome of acquired aplastic anemia has improved markedly with the introduction of immunosuppressive therapy using antithymocyte globulin and cyclosporine, a significant proportion of patients subsequently relapse and require second-line therapy. However, detailed analyses of relapses in aplastic anemia children are limited. DESIGN AND METHODS: We previously conducted two prospective multicenter trials of immunosuppressive therapy for children with aplastic anemia: AA-92 and AA-97, which began in 1992 and 1997, respectively. In this study, we assessed the relapse rate, risk factors for relapse, and the response to second-line treatment in children with aplastic anemia treated with antithymocyte globulin and cyclosporine. RESULTS: From 1992 to 2007, we treated 441 children with aplastic anemia with standard immunosuppressive therapy. Among the 264 patients who responded to immunosuppressive therapy, 42 (15.9%) relapsed. The cumulative incidence of relapse was 11.9% at 10 years. Multivariate analysis revealed that relapse risk was significantly associated with an immunosuppressive therapy regimen using danazol (relative risk, 3.15; P=0.001) and non-severe aplastic anemia (relative risk, 2.51; P=0.02). Seventeen relapsed patients received additional immunosuppressive therapy with antithymocyte globulin and cyclosporine. Eight patients responded within 6 months. Seven of nine non-responders to second immunosuppressive therapy received hematopoietic stem cell transplantation and five are alive. Eleven patients underwent hematopoietic stem cell transplantation directly and seven are alive. CONCLUSIONS: In the present study, the cumulative incidence of relapse at 10 years was relatively low compared to that in other studies mainly involving adult patients. A multicenter prospective study is warranted to establish optimal therapy for children with aplastic anemia.
BACKGROUND: Although the therapeutic outcome of acquired aplastic anemia has improved markedly with the introduction of immunosuppressive therapy using antithymocyte globulin and cyclosporine, a significant proportion of patients subsequently relapse and require second-line therapy. However, detailed analyses of relapses in aplastic anemiachildren are limited. DESIGN AND METHODS: We previously conducted two prospective multicenter trials of immunosuppressive therapy for children with aplastic anemia: AA-92 and AA-97, which began in 1992 and 1997, respectively. In this study, we assessed the relapse rate, risk factors for relapse, and the response to second-line treatment in children with aplastic anemia treated with antithymocyte globulin and cyclosporine. RESULTS: From 1992 to 2007, we treated 441 children with aplastic anemia with standard immunosuppressive therapy. Among the 264 patients who responded to immunosuppressive therapy, 42 (15.9%) relapsed. The cumulative incidence of relapse was 11.9% at 10 years. Multivariate analysis revealed that relapse risk was significantly associated with an immunosuppressive therapy regimen using danazol (relative risk, 3.15; P=0.001) and non-severe aplastic anemia (relative risk, 2.51; P=0.02). Seventeen relapsed patients received additional immunosuppressive therapy with antithymocyte globulin and cyclosporine. Eight patients responded within 6 months. Seven of nine non-responders to second immunosuppressive therapy received hematopoietic stem cell transplantation and five are alive. Eleven patients underwent hematopoietic stem cell transplantation directly and seven are alive. CONCLUSIONS: In the present study, the cumulative incidence of relapse at 10 years was relatively low compared to that in other studies mainly involving adult patients. A multicenter prospective study is warranted to establish optimal therapy for children with aplastic anemia.
Authors: B M Camitta; E D Thomas; D G Nathan; R P Gale; K J Kopecky; J M Rappeport; G Santos; E C Gordon-Smith; R Storb Journal: Blood Date: 1979-03 Impact factor: 22.113
Authors: Hiroki Yamaguchi; Gabriela M Baerlocher; Peter M Lansdorp; Stephen J Chanock; Olga Nunez; Elaine Sloand; Neal S Young Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: Scott C Howard; Paula E Naidu; X Joan Hu; Michael R Jeng; Carlos Rodriguez-Galindo; Martha D Rieman; Winfred C Wang Journal: Pediatr Blood Cancer Date: 2004-10 Impact factor: 3.167
Authors: A Bacigalupo; M Chaple; J Hows; M T Van Lint; S McCann; D Milligan; J Chessells; A H Goldstone; J Ottolander; E T van't Veer Journal: Br J Haematol Date: 1993-01 Impact factor: 6.998
Authors: Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young Journal: Lancet Date: 2003-11-15 Impact factor: 79.321
Authors: H Schrezenmeier; P Marin; A Raghavachar; S McCann; J Hows; E Gluckman; C Nissen; E T van't Veer-Korthof; P Ljungman; W Hinterberger Journal: Br J Haematol Date: 1993-10 Impact factor: 6.998
Authors: Craig M Forester; Sarah E Sartain; Dongjing Guo; Marian H Harris; Olga K Weinberg; Mark D Fleming; Wendy B London; David A Williams; Inga Hofmann Journal: Am J Hematol Date: 2015-03-02 Impact factor: 10.047
Authors: David A Williams; Carolyn Bennett; Alison Bertuch; Monica Bessler; Thomas Coates; Seth Corey; Yigal Dror; James Huang; Jeffrey Lipton; Timothy S Olson; Ulrike M Reiss; Zora R Rogers; Colin Sieff; Adrianna Vlachos; Kelly Walkovich; Winfred Wang; Akiko Shimamura Journal: Pediatr Blood Cancer Date: 2013-11-27 Impact factor: 3.167
Authors: Christopher J Gamper; Clifford M Takemoto; Allen R Chen; Heather J Symons; David M Loeb; James F Casella; Amy E Dezern; Karen E King; Andrea M McGonigle; Richard J Jones; Robert A Brodsky Journal: J Pediatr Hematol Oncol Date: 2016-11 Impact factor: 1.289
Authors: Zora R Rogers; Taizo A Nakano; Timothy S Olson; Alison A Bertuch; Winfred Wang; Alfred Gillio; Thomas D Coates; Anjulika Chawla; Paul Castillo; Peter Kurre; Christopher Gamper; Carolyn M Bennett; Sarita Joshi; Amy E Geddis; Jessica Boklan; Grzegorz Nalepa; Jennifer A Rothman; James N Huang; Gary M Kupfer; Michaela Cada; Bertil Glader; Kelly J Walkovich; Alexis A Thompson; Rabi Hanna; Adrianna Vlachos; Maggie Malsch; Edie A Weller; David A Williams; Akiko Shimamura Journal: Haematologica Date: 2019-04-04 Impact factor: 9.941